{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:40:15Z","timestamp":1792788015073,"version":"4.5.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T00:00:00Z","timestamp":1782691200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T00:00:00Z","timestamp":1789516800000},"content-version":"vor","delay-in-days":79,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Shenzhen Science and Technology Innovation Committee","award":["JCYJ20250604143712016"],"award-info":[{"award-number":["JCYJ20250604143712016"]}],"id":[{"id":"https:\/\/ror.org\/017n8df75","id-type":"ROR","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100003453","name":"Natural Science Foundation of Guangdong Province","doi-asserted-by":"publisher","award":["2024A1515012581"],"award-info":[{"award-number":["2024A1515012581"]}],"id":[{"id":"10.13039\/501100003453","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["No. 82172579, No.82303879, No.82303875"],"award-info":[{"award-number":["No. 82172579, No.82303879, No.82303875"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"National Science and Technology Major Project of China","award":["2024ZD0520402"],"award-info":[{"award-number":["2024ZD0520402"]}]},{"name":"Clinical Trials Project (5010 Project) of Sun Yat-sen University","award":["No. 5010-2023001"],"award-info":[{"award-number":["No. 5010-2023001"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med"],"DOI":"10.1186\/s12916-026-05029-x","type":"journal-article","created":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T12:28:19Z","timestamp":1782736099000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Adjuvant systemic therapy versus active surveillance after resection following conversion therapy for hepatocellular carcinoma: a propensity score matched study"],"prefix":"10.1186","volume":"24","author":[{"given":"Benyi","family":"He","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zehao","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junyu","family":"Gan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhijun","family":"Zuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiahua","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Mei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenmin","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Longzhou","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rongce","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rongping","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lianghe","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,29]]},"reference":[{"issue":"3","key":"5029_CR1","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229\u201363.","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"5029_CR2","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1038\/s41572-020-00240-3","volume":"7","author":"JM Llovet","year":"2021","unstructured":"Llovet JM, Kelley RK, Villanueva A, Singal AG, Pikarsky E, Roayaie S, et al. Hepatocellular carcinoma. Nat Rev Dis Primers. 2021;7(1):6.","journal-title":"Nat Rev Dis Primers"},{"issue":"9","key":"5029_CR3","doi-asserted-by":"publisher","first-page":"2155","DOI":"10.1111\/liv.12818","volume":"35","author":"JW Park","year":"2015","unstructured":"Park JW, Chen M, Colombo M, Roberts LR, Schwartz M, Chen PJ, et al. Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE Study. Liver Int. 2015;35(9):2155\u201366.","journal-title":"Liver Int"},{"issue":"5","key":"5029_CR4","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1038\/s41575-020-00395-0","volume":"18","author":"JM Llovet","year":"2021","unstructured":"Llovet JM, De Baere T, Kulik L, Haber PK, Greten TF, Meyer T, et al. Locoregional therapies in the era of molecular and immune treatments for hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol. 2021;18(5):293\u2013313.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"11","key":"5029_CR5","doi-asserted-by":"publisher","first-page":"2090","DOI":"10.1093\/annonc\/mdw323","volume":"27","author":"M I","year":"2016","unstructured":"I M, S S, S T, M M, K Y, I Y, et al. Sorafenib plus hepatic arterial infusion chemotherapy with cisplatin versus sorafenib for advanced hepatocellular carcinoma: randomized phase II trial. Annals Oncol : official J Eur Soc Med Oncol. 2016;27(11):2090\u20136.","journal-title":"Annals Oncol : official J Eur Soc Med Oncol"},{"issue":"3","key":"5029_CR6","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1159\/000538558","volume":"13","author":"M K","year":"2024","unstructured":"K. M. Immune Checkpoint Inhibitors plus Anti-VEGF\/Tyrosine Kinase Inhibitors Combined with TACE (Triple Therapy) in Unresectable Hepatocellular Carcinoma. Liver cancer. 2024;13(3):227\u201334.","journal-title":"Liver cancer"},{"issue":"6","key":"5029_CR7","doi-asserted-by":"publisher","first-page":"498","DOI":"10.3322\/caac.70018","volume":"75","author":"D Moris","year":"2025","unstructured":"Moris D, Martinino A, Schiltz S, Allen PJ, Barbas A, Sudan D, et al. Advances in the treatment of hepatocellular carcinoma: An overview of the current and evolving therapeutic landscape for clinicians. Cancer J Clin. 2025;75(6):498\u2013527.","journal-title":"Cancer J Clin"},{"issue":"4","key":"5029_CR8","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/S2468-1253(24)00247-4","volume":"10","author":"BY Zhong","year":"2025","unstructured":"Zhong BY, Fan W, Guan JJ, Peng Z, Jia Z, Jin H, et al. Combination locoregional and systemic therapies in hepatocellular carcinoma. Lancet Gastroenterol Hepatol. 2025;10(4):369\u201386.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"13","key":"5029_CR9","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1016\/S1470-2045(15)00198-9","volume":"16","author":"J Bruix","year":"2015","unstructured":"Bruix J, Takayama T, Mazzaferro V, Chau GY, Yang J, Kudo M, et al. Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2015;16(13):1344\u201354.","journal-title":"Lancet Oncol"},{"key":"5029_CR10","doi-asserted-by":"publisher","first-page":"S1230","DOI":"10.1016\/j.annonc.2024.08.2279","volume":"35","author":"A Yopp","year":"2024","unstructured":"Yopp A, Kudo M, Chen M, Cheng AL, Kaseb AO, Lee HC, et al. LBA39 Updated efficacy and safety data from IMbrave050: Phase III study of adjuvant atezolizumab (atezo) + bevacizumab (bev) vs active surveillance in patients (pts) with resected or ablated high-risk hepatocellular carcinoma (HCC). Ann Oncol. 2024;35:S1230.","journal-title":"Ann Oncol"},{"issue":"3","key":"5029_CR11","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1038\/s41591-023-02786-7","volume":"30","author":"K Wang","year":"2024","unstructured":"Wang K, Xiang YJ, Yu HM, Cheng YQ, Liu ZH, Qin YY, et al. Adjuvant sintilimab in resected high-risk hepatocellular carcinoma: a randomized, controlled, phase 2 trial. Nat Med. 2024;30(3):708\u201315.","journal-title":"Nat Med"},{"key":"5029_CR12","doi-asserted-by":"publisher","DOI":"10.1159\/000549793","author":"Q Lin","year":"2025","unstructured":"Lin Q, Peng W, Yu X, Xie F, Wang X, Song Z, et al. Pathological complete response after systemic therapy and curative resection in initially unresectable hepatocellular carcinoma: feasibility of a Tumor-Free with Drug-Free strategy. Liver Cancer. 2025. https:\/\/doi.org\/10.1159\/000549793.","journal-title":"Liver Cancer"},{"issue":"4","key":"5029_CR13","doi-asserted-by":"publisher","first-page":"432","DOI":"10.5582\/bst.2025.01162","volume":"19","author":"Y Cao","year":"2025","unstructured":"Cao Y, Pan L, Ran Z, Zhang W, Li J, Li X, et al. Conversion therapy followed by surgery and adjuvant therapy improves survival in Barcelona C stage hepatocellular carcinoma \u2015 A propensity score-matched analysis. BST. 2025;19(4):432\u201344.","journal-title":"BST"},{"issue":"2","key":"5029_CR14","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.jhep.2024.08.028","volume":"82","author":"B Sangro","year":"2025","unstructured":"Sangro B, Argemi J, Ronot M, Paradis V, Meyer T, Mazzaferro V, et al. EASL Clinical Practice Guidelines on the management of hepatocellular carcinoma. J Hepatol. 2025;82(2):315\u201374.","journal-title":"J Hepatol"},{"issue":"6","key":"5029_CR15","doi-asserted-by":"publisher","first-page":"1922","DOI":"10.1097\/HEP.0000000000000466","volume":"78","author":"AG Singal","year":"2023","unstructured":"Singal AG, Llovet JM, Yarchoan M, Mehta N, Heimbach JK, Dawson LA, et al. AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma. Hepatology. 2023;78(6):1922\u201365.","journal-title":"Hepatology"},{"issue":"2","key":"5029_CR16","first-page":"223","volume":"14","author":"XB H Z","year":"2024","unstructured":"H Z XB. Consensus of Chinese Experts on Neoadjuvant and Conversion Therapies for Hepatocellular Carcinoma: 2023 Update. Liver cancer. 2024;14(2):223\u201338.","journal-title":"Liver cancer"},{"issue":"6","key":"5029_CR17","doi-asserted-by":"publisher","first-page":"1661","DOI":"10.1007\/s12072-024-10732-z","volume":"18","author":"G Lau","year":"2024","unstructured":"Lau G, Obi S, Zhou J, Tateishi R, Qin S, Zhao H, et al. APASL clinical practice guidelines on systemic therapy for hepatocellular carcinoma-2024. Hepatol Int. 2024;18(6):1661\u201383.","journal-title":"Hepatol Int"},{"issue":"6","key":"5029_CR18","first-page":"779","volume":"14","author":"J Zhou","year":"2025","unstructured":"Zhou J, Sun H, Wang Z, Cong W, Zeng M, Zhou W, et al. China Liver Cancer Guidelines for the Diagnosis and Treatment of Hepatocellular Carcinoma (2024 Edition). Liver Cancer. 2025;14(6):779\u2013835.","journal-title":"Liver Cancer"},{"issue":"1","key":"5029_CR19","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1055\/s-0030-1247132","volume":"30","author":"R Lencioni","year":"2010","unstructured":"Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis. 2010;30(1):52\u201360.","journal-title":"Semin Liver Dis"},{"issue":"11","key":"5029_CR20","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1056\/NEJM199603143341104","volume":"334","author":"V Mazzaferro","year":"1996","unstructured":"Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med. 1996;334(11):693\u20139.","journal-title":"N Engl J Med"},{"issue":"1","key":"5029_CR21","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/S1470-2045(08)70284-5","volume":"10","author":"V Mazzaferro","year":"2009","unstructured":"Mazzaferro V, Llovet JM, Miceli R, Bhoori S, Schiavo M, Mariani L, et al. Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncol. 2009;10(1):35\u201343.","journal-title":"Lancet Oncol"},{"issue":"10126","key":"5029_CR22","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1016\/S0140-6736(18)30207-1","volume":"391","author":"M Kudo","year":"2018","unstructured":"Kudo M, Finn RS, Qin S, Han KH, Ikeda K, Piscaglia F, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet. 2018;391(10126):1163\u201373.","journal-title":"Lancet"},{"issue":"20","key":"5029_CR23","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","volume":"382","author":"RS Finn","year":"2020","unstructured":"Finn RS, Qin S, Ikeda M, Galle PR, Ducreux M, Kim TY, et al. Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. N Engl J Med. 2020;382(20):1894\u2013905.","journal-title":"N Engl J Med"},{"issue":"8","key":"5029_CR24","doi-asserted-by":"publisher","first-page":"EVIDoa2100070","DOI":"10.1056\/EVIDoa2100070","volume":"1","author":"GK Abou-Alfa","year":"2022","unstructured":"Abou-Alfa GK, Lau G, Kudo M, Chan SL, Kelley RK, Furuse J, et al. Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma. NEJM Evid. 2022;1(8):EVIDoa2100070.","journal-title":"NEJM Evid"},{"key":"5029_CR25","doi-asserted-by":"crossref","unstructured":"Yau T, Galle PR, Decaens T, Sangro B, Qin S, Fonseca LG et al. da,. Nivolumab plus ipilimumab versus lenvatinib or sorafenib as first-line treatment for unresectable hepatocellular carcinoma (CheckMate 9DW): an open-label, randomised, phase 3 trial. The Lancet. 2025;405,1851\u20131864.","DOI":"10.1016\/S0140-6736(25)00403-9"},{"issue":"10415","key":"5029_CR26","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1016\/S0140-6736(23)01796-8","volume":"402","author":"S Qin","year":"2023","unstructured":"Qin S, Chen M, Cheng AL, Kaseb AO, Kudo M, Lee HC, et al. Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial. Lancet. 2023;402(10415):1835\u201347.","journal-title":"Lancet"},{"issue":"4","key":"5029_CR27","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1038\/s41571-024-00868-0","volume":"21","author":"JM Llovet","year":"2024","unstructured":"Llovet JM, Pinyol R, Yarchoan M, Singal AG, Marron TU, Schwartz M, et al. Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma. Nat Rev Clin Oncol. 2024;21(4):294\u2013311.","journal-title":"Nat Rev Clin Oncol"},{"issue":"6","key":"5029_CR28","first-page":"687","volume":"14","author":"DL Yang","year":"2025","unstructured":"Yang DL, Peng N, Nong JL, Chen K, Su Z, Yu YQ, et al. Survival Benefit of Hepatectomy after Complete or Partial Response to Conversion Therapy in Unresectable Hepatocellular Carcinoma (GUIDANCE003): A Multicenter Study. Liver Cancer. 2025;14(6):687\u2013703.","journal-title":"Liver Cancer"},{"issue":"4","key":"5029_CR29","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1159\/000543994","volume":"14","author":"M Piao","year":"2025","unstructured":"Piao M, Li C, Huang Z, Zhang N, Li J, Yang X, et al. Conversion Surgery after Immune Checkpoint Inhibitor-Based Combination Therapy for Initially Unresectable Hepatocellular Carcinoma: A Retrospective Cohort Study. Liver Cancer. 2025;14(4):456\u201373.","journal-title":"Liver Cancer"},{"issue":"10","key":"5029_CR30","doi-asserted-by":"publisher","first-page":"e1541","DOI":"10.1634\/theoncologist.2019-0944","volume":"25","author":"W Md","year":"2020","unstructured":"Md W, C L, Ly LLHX. Early and Late Recurrence of Hepatitis B Virus-Associated Hepatocellular Carcinoma. Oncologist. 2020;25(10):e1541\u201351.","journal-title":"Oncologist"},{"key":"5029_CR31","doi-asserted-by":"publisher","first-page":"2321","DOI":"10.1245\/s10434-020-08452-3","volume":"27","author":"T Di","year":"2020","unstructured":"Di T, F B, Jm DM, K H, Az S. Recurrence Patterns and Outcomes after Resection of Hepatocellular Carcinoma within and beyond the Barcelona Clinic Liver Cancer Criteria. Ann Surg Oncol. 2020;27:2321\u201331.","journal-title":"Ann Surg Oncol"},{"issue":"3","key":"5029_CR32","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1158\/1078-0432.CCR-08-1608","volume":"15","author":"QG Xy","year":"2009","unstructured":"Xy QG, Sj W, I Q. Overexpression of PD-L1 significantly associates with tumor aggressiveness and postoperative recurrence in human hepatocellular carcinoma. Clin Cancer Res. 2009;15(3):971\u20139.","journal-title":"Clin Cancer Res"},{"issue":"4","key":"5029_CR33","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1038\/nrclinonc.2017.194","volume":"15","author":"JG Hiller","year":"2018","unstructured":"Hiller JG, Perry NJ, Poulogiannis G, Riedel B, Sloan EK. Perioperative events influence cancer recurrence risk after surgery. Nat Rev Clin Oncol. 2018;15(4):205\u201318.","journal-title":"Nat Rev Clin Oncol"},{"issue":"10515","key":"5029_CR34","doi-asserted-by":"publisher","first-page":"2089","DOI":"10.1016\/S0140-6736(25)01720-9","volume":"406","author":"Z Wang","year":"2025","unstructured":"Wang Z, Fan J, Zhou S, Sun Y, Liang F, Ji Y, et al. Perioperative camrelizumab plus rivoceranib versus surgery alone in patients with resectable hepatocellular carcinoma at intermediate or high risk of recurrence (CARES-009): a randomised phase 2\/3 trial. Lancet. 2025;406(10515):2089\u201399.","journal-title":"Lancet"},{"issue":"2","key":"5029_CR35","first-page":"155","volume":"12","author":"Y Wt","year":"2021","unstructured":"Wt Y, C L, Lq Y, Hb Q, Md W, Xf X, et al. Predictors and long-term prognosis of early and late recurrence for patients undergoing hepatic resection of hepatocellular carcinoma: a large-scale multicenter study. Hepatobiliary Surg Nutr. 2021;12(2):155\u201368.","journal-title":"Hepatobiliary Surg Nutr"}],"container-title":["BMC Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12916-026-05029-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-026-05029-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-026-05029-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T01:18:01Z","timestamp":1789521481000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12916-026-05029-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,29]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["5029"],"URL":"https:\/\/doi.org\/10.1186\/s12916-026-05029-x","relation":{},"ISSN":["1741-7015"],"issn-type":[{"value":"1741-7015","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,29]]},"assertion":[{"value":"8 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was approved by the Institutional Review Board\/Ethics Committee of Sun Yat-sen University Cancer Center (Approval No. B2025-237-01). The requirement for informed consent was exempted by the ethics committee due to the retrospective design and use of anonymized data.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No individual patient data are presented in this paper, and consent for publication was not required.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"494"}}